Boston Innovation Center- DMPK & Bioanalytical
Services
Your U.S. Partner for Preclinical DMPK & Bioanalysis
Unlock the Full Potential of Your Molecular Discovery Program with Medicilon's Expertise
As part of Medicilon’s dual-site global operations (Boston, USA and Shanghai, China), the Boston site offers non-GLP validated assay development with workflows seamlessly transferable to GLP execution in Shanghai, ensuring continuity from early discovery through IND-enabling studies.
Why Choose Medicilon Boston?
Medicilon Boston combines local accessibility with global expertise, delivering non-GLP DMPK and bioanalytical studies tailored to U.S. biotech and pharma.
Strategic U.S. Location
Supporting biotech and pharma across Massachusetts, Greater Boston, and North America.
Validated DMPK Assays
From metabolic stability to CYP450 profiling and transporter studies.
Advanced Bioanalytical Capabilities
LC-MS/MS, ligand binding assays, and oligonucleotide quantification.
Seamless IND Support
Non-GLP studies in Boston with GLP-ready workflows transferable to Shanghai.
Expertise in Emerging Modalities
PROTACs, ADCs, peptides, siRNA, mRNA, and more.
Trusted Partner
Proven experience delivering reproducible data that supports IND submissions.
In Vitro ADME Assays
Boston offers validated in vitro ADME assays to assess absorption, metabolism, enzyme activity, and transporter interactions across multiple species.
Metabolic stability (microsomes, hepatocytes, S9 fractions)
Plasma/serum/whole blood stability.
Plasma protein binding (multi-species)
CYP450 enzyme inhibition, induction, TDI
Transporter assays (P-gp, BCRP, OATPs, OCTs, MATEs, BSEP, MRPs)
Permeability (Caco-2, MDCK) and BBB penetration studies
Kinetic solubility, blood/plasma partitioning, GSH-trapping
Mini-Ames and Ames genotoxicity testing
In Vivo PK & TK Studies
Our Boston lab provides non-GLP pharmacokinetics and toxicokinetics in multiple species to evaluate systemic exposure, bioavailability, and tissue distribution
Species:
Mouse, Rat, Rabbit, Dog, Monkey (Shanghai site)
Administration Routes:
IV, PO, SC, IM, IP, topical, transdermal, intrathecal
Capabilities:
Cassette dosing, LC-MS/MS quantification, tissue distribution, microsampling, isotope balance studies
Surgical expertise:
Venous/biliary cannulation, infusion pump, tissue biopsy
Optimize your drug development with Medicilon at our state of the art Boston Innovation Center
Preclinical small molecule Studies
Bioanalytical Platforms
In vivo ADME studies capture complex biological interactions, making them indispensable for:
Bioavailability & Dosing Strategies
Tissue Distribution & Excretion Pathways
Regulatory Filings
Bioanalytical Platforms
Medicilon Boston delivers sensitive bioanalytical solutions for small molecules, biologics, and advanced modalities, combining LC-MS/MS, LBAs, and cell-based assays
LC-MS/MS Quantification
Small molecules, ADC payloads, sensitivity ~1 ng/mL
Ligand Binding Assays
ADA detection, conjugated/total antibody measurement
Cell-Based Assays
ELISA, multiplex cytokine profiling, Western blot, flow cytometry
Oligonucleotide Analysis
siRNA, ASOs, mRNA with CV <10% reproducibility
Immunogenicity Support
ADCC, ADCP, CDC assays for biologics
Custom Modalities
PROTAC and ADC PK, linker/payload quantification, peptide stability
State-of-the-art facility
Robust Instruments
Custom Solutions
Tailored studies to match your project’s unique needs
Expert Teams
Over 20 years of experience delivering reliable data
Regulatory Compliance
IND/NDA-ready packages aligned with global standards
Partner with Medicilon to accelerate your drug discovery
Case Studies
Proven Results with Medicilon
Medicilon Boston demonstrates expertise across emerging drug modalities, generating high-quality non-GLP PK and BA data to guide therapeutic development.
PROTAC ARD-2128
Low clearance (1.2 mL/min/kg), high oral bioavailability (67%), T1/2 ~18 – 28 h, excellent plasma and microsomal stability across species.
ADC Molecule
Customized PK with precise quantitation of warhead, linker, and payload.
siRNA Drug
siRNA plasma and tissue quantification demonstrated 1- 10 ng/mL sensitivity, validated across hundreds of samples with high reproducibility (CV <10%).
Frequently Asked Questions
Have questions about DMPK/ Bioanalytical Studies?
What makes the Boston site unique?
Medicilon Boston provides U.S.-based biotech and pharma with fast, local access to DMPK and BA expertise, offering validated assays and FDA-focused IND support.
What report format is provided?
Reports are delivered in non-GLP format, with reproducible data supporting decision-making, method transfer, and readiness for GLP studies.
Which compounds can Boston handle?
The site supports small molecules, biologics, ADCs, PROTACs, peptides, siRNA, ASOs, and mRNA drugs, with validated bioanalytical methods for even the most challenging modalities.
How quickly can I get results from Boston?
We offer rapid turnaround times with transparent updates. Reports are delivered in non-GLP format, providing high-quality, reproducible data to support decision-making, method transfer, and readiness for subsequent GLP studies.
Can Boston support IND submissions to the FDA?
Our Boston team provides non-GLP IND-enabling packages with validated data designed to streamline FDA regulatory pathways.
Your Trusted Local Partner Recognized Globally
From early discovery to IND-enabling studies, Medicilon’s integrated solutions and expert teams are here to support you at every step of drug development.
